GW274150

GW274150 is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM) . GW274150 also displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS) . GW274150 exerts a protective role in an acute model of lung injury inflammation[1][2].

Product Specifications

CAS Number

[210354-22-6]

UNSPSC

12352211

Target

NO Synthase

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/GW274150.html

Concentration

10mM

Purity

98.42

Solubility

H2O : ≥ 62 mg/mL

Smiles

N[C@@H](CCSCCNC(C)=N)C(O)=O

Molecular Formula

C8H17N3O2S

Molecular Weight

219.30

References & Citations

[1]Alderton WK, et al. GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo.Br J Pharmacol. 2005 Jun;145 (3) :301-12.|[2]Dugo L, et al. Effects of GW274150, a novel and selective inhibitor of iNOS activity, in acute lung inflammation. Br J Pharmacol. 2004 Mar;141 (6) :979-87. Epub 2004 Feb|[3]Broom L, et al. Neuroprotection by the selective iNOS inhibitor GW274150 in a model of Parkinson disease.Free Radic Biol Med. 2011 Mar 1;50 (5) :633-40.